rug discovery is long and winding, and riddled with high-cost failure at every turn. A newly unveiled Cambridge startup aims to streamline the process with a platform it’s calling “CRISPRomics” — and it has recruited some top-flight talent to lead the effort.

The two-year-old company — KSQ Therapeutics — just emerged from stealth, announcing a $76 million financing round and a new CEO: Dr. David Meeker, former chief executive of Genzyme. He stepped down from his post at the merged Sanofi-Genzyme (SNY) this past April.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.